LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Home・Listă Acțiuni・Kura Oncology Inc

Kura Oncology Inc

Închisă

SectorSănătate

10.28 14.99

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

8.94

Maxim

10.37

Indicatori cheie
By Trading Economics
Venit	7.7M -73M
Vânzări	929K 18M
Marjă de profit	-401.495
Angajați	260
EBITDA	7.4M -78M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+205.76% upside

Dividende
By Dow Jones
Următoarele câștiguri	6 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-31M 813M
Deschiderea anterioară	-4.71
Închiderea anterioară	10.28

Sentimentul știrilor

By Acuity

55%

45%

286 / 345 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

5.575 / 6.6 Suport & Rezistență

Kura Oncology Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

19 mai 2026, 20:36 UTC

Achiziții, Fuziuni, Preluări

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19 mai 2026, 23:47 UTC

Market Talk

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19 mai 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19 mai 2026, 23:28 UTC

Market Talk

Câștiguri

Global Forex and Fixed Income Roundup: Market Talk

19 mai 2026, 23:28 UTC

Market Talk

Câștiguri

F&P Healthcare's Outlook Key for Investors -- Market Talk

19 mai 2026, 23:10 UTC

Market Talk

Global Equities Roundup: Market Talk

19 mai 2026, 23:10 UTC

Market Talk

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19 mai 2026, 22:02 UTC

Câștiguri

ZTO Express (Cayman): Di Xu to Resign From Board

19 mai 2026, 22:01 UTC

Câștiguri

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19 mai 2026, 22:01 UTC

Câștiguri

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19 mai 2026, 22:00 UTC

Câștiguri

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19 mai 2026, 21:37 UTC

Câștiguri

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19 mai 2026, 21:31 UTC

Achiziții, Fuziuni, Preluări

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19 mai 2026, 21:01 UTC

Câștiguri

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19 mai 2026, 20:58 UTC

Câștiguri

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19 mai 2026, 20:46 UTC

Acțiuni populare

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19 mai 2026, 20:43 UTC

Market Talk

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19 mai 2026, 20:34 UTC

Câștiguri

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19 mai 2026, 20:32 UTC

Câștiguri

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19 mai 2026, 20:32 UTC

Câștiguri

James Hardie Industries 4Q EPS 5c >JHX

19 mai 2026, 20:32 UTC

Câștiguri

James Hardie Industries 4Q Sales $1.4B >JHX

19 mai 2026, 20:21 UTC

Achiziții, Fuziuni, Preluări

Analog Devices to Buy Empower Semiconductor for $1.5B

19 mai 2026, 20:18 UTC

Market Talk

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19 mai 2026, 20:13 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19 mai 2026, 20:13 UTC

Market Talk

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19 mai 2026, 20:03 UTC

Achiziții, Fuziuni, Preluări

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19 mai 2026, 20:03 UTC

Achiziții, Fuziuni, Preluări

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19 mai 2026, 20:02 UTC

Achiziții, Fuziuni, Preluări

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19 mai 2026, 20:02 UTC

Achiziții, Fuziuni, Preluări

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19 mai 2026, 19:23 UTC

Market Talk

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Comparație

Modificare preț

Kura Oncology Inc Așteptări

Obiectiv de preț

By TipRanks

205.76% sus

Prognoză pe 12 luni

Medie 28.13 USD 205.76%

Maxim 40 USD

Minim 15 USD

În baza a 10 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruKura Oncology Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

10 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 10 analiști care au acordat evaluări ale acțiunilor Kura Oncology Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

5.575 / 6.6Suport & Rezistență

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

286 / 345 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.